 Shares of Inovio Pharmaceuticals Inc. INO, 0.75 gained 5.9 in premarket trading on Tuesday after the company said it can move forward with the Phase 3 clinical trial for its experimental COVID-19 shot now that the Food and Drug Administration has lifted its partial clinical hold. Inovio had announced the partial clinical hold in September of last year. 